JP6664219B2 - 幹細胞増強治療法 - Google Patents

幹細胞増強治療法 Download PDF

Info

Publication number
JP6664219B2
JP6664219B2 JP2015527590A JP2015527590A JP6664219B2 JP 6664219 B2 JP6664219 B2 JP 6664219B2 JP 2015527590 A JP2015527590 A JP 2015527590A JP 2015527590 A JP2015527590 A JP 2015527590A JP 6664219 B2 JP6664219 B2 JP 6664219B2
Authority
JP
Japan
Prior art keywords
seq
antibody
cells
antibodies
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015527590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526446A (ja
JP2015526446A5 (https=
Inventor
バンダッド，シンシア
Original Assignee
ミネルバ バイオテクノロジーズ コーポレーション
ミネルバ バイオテクノロジーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/060684 external-priority patent/WO2013059373A2/en
Priority claimed from PCT/US2013/025981 external-priority patent/WO2013123084A1/en
Application filed by ミネルバ バイオテクノロジーズ コーポレーション, ミネルバ バイオテクノロジーズ コーポレーション filed Critical ミネルバ バイオテクノロジーズ コーポレーション
Publication of JP2015526446A publication Critical patent/JP2015526446A/ja
Publication of JP2015526446A5 publication Critical patent/JP2015526446A5/ja
Application granted granted Critical
Publication of JP6664219B2 publication Critical patent/JP6664219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015527590A 2012-08-14 2013-08-14 幹細胞増強治療法 Active JP6664219B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261683155P 2012-08-14 2012-08-14
US61/683,155 2012-08-14
US201261684654P 2012-08-17 2012-08-17
US61/684,654 2012-08-17
US201261693712P 2012-08-27 2012-08-27
US61/693,712 2012-08-27
USPCT/US2012/060684 2012-10-17
PCT/US2012/060684 WO2013059373A2 (en) 2011-10-17 2012-10-17 Media for stem cell proliferation and induction
PCT/US2013/025981 WO2013123084A1 (en) 2012-02-13 2013-02-13 Method for detecting circulating fetal cells
USPCT/US2013/025981 2013-02-13
US201361837560P 2013-06-20 2013-06-20
US61/837,560 2013-06-20
PCT/US2013/055015 WO2014028668A2 (en) 2012-08-14 2013-08-14 Stem cell enhancing therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017238427A Division JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法

Publications (3)

Publication Number Publication Date
JP2015526446A JP2015526446A (ja) 2015-09-10
JP2015526446A5 JP2015526446A5 (https=) 2016-10-06
JP6664219B2 true JP6664219B2 (ja) 2020-03-13

Family

ID=50101604

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015527590A Active JP6664219B2 (ja) 2012-08-14 2013-08-14 幹細胞増強治療法
JP2017238427A Active JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法
JP2020037396A Pending JP2020109101A (ja) 2012-08-14 2020-03-05 幹細胞増強治療法
JP2021181985A Pending JP2022025136A (ja) 2012-08-14 2021-11-08 幹細胞増強治療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017238427A Active JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法
JP2020037396A Pending JP2020109101A (ja) 2012-08-14 2020-03-05 幹細胞増強治療法
JP2021181985A Pending JP2022025136A (ja) 2012-08-14 2021-11-08 幹細胞増強治療法

Country Status (8)

Country Link
US (2) US9932407B2 (https=)
EP (1) EP2885000A4 (https=)
JP (4) JP6664219B2 (https=)
CN (3) CN104717980A (https=)
AU (2) AU2013302620B2 (https=)
CA (1) CA2882222A1 (https=)
IL (1) IL237228B (https=)
WO (1) WO2014028668A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3130607B1 (en) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
AU2015243948B2 (en) 2014-04-07 2020-10-15 Minerva Biotechnologies Corporation Anti-NME antibody
CN116199790A (zh) * 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
KR102486507B1 (ko) * 2016-04-08 2023-01-09 아이티아이 헬스, 인크. 플렉틴-1 결합 항체 및 그의 용도
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
JP7379347B2 (ja) * 2017-10-11 2023-11-14 ジィールバイオ，インコーポレーテッド プレクチン１結合抗体およびその使用
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
CN120484122A (zh) * 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
EP4161970A4 (en) 2020-06-08 2024-07-10 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JP2005508839A (ja) * 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
EP2329822A1 (en) * 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
WO2003089451A2 (en) * 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
CA2491017A1 (en) * 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
US20090075926A1 (en) 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP3130607B1 (en) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
CN102272290B (zh) * 2008-10-09 2018-08-14 米纳瓦生物技术公司 用于在细胞中诱导多能性的方法
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
US8628959B2 (en) * 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
EP3228629A1 (en) * 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells

Also Published As

Publication number Publication date
JP6757712B2 (ja) 2020-09-23
JP2015526446A (ja) 2015-09-10
AU2018220126B2 (en) 2020-07-23
IL237228B (en) 2021-03-25
CN108175856B (zh) 2024-01-26
EP2885000A4 (en) 2015-12-23
AU2013302620A1 (en) 2015-04-02
US20170121406A1 (en) 2017-05-04
AU2013302620B2 (en) 2018-08-02
EP2885000A2 (en) 2015-06-24
AU2018220126A1 (en) 2018-09-13
US20150299334A1 (en) 2015-10-22
JP2020109101A (ja) 2020-07-16
CA2882222A1 (en) 2014-02-20
CN108175856A (zh) 2018-06-19
JP2018070640A (ja) 2018-05-10
JP2022025136A (ja) 2022-02-09
US9932407B2 (en) 2018-04-03
CN111388664A (zh) 2020-07-10
IL237228A0 (en) 2015-04-30
WO2014028668A2 (en) 2014-02-20
WO2014028668A3 (en) 2014-05-01
CN104717980A (zh) 2015-06-17

Similar Documents

Publication Publication Date Title
JP6664219B2 (ja) 幹細胞増強治療法
JP6823094B2 (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP7011574B2 (ja) Ｆｌｔ３及びｃｄ３に対する抗体構築物
CN104136037B (zh) 高亲和力SIRP‑α试剂
CN103459595B (zh) 针对人前列腺素e2受体ep4的抗体
EP2688585B1 (en) Methods and compositions for improving antiangiogenic therapy with anti-integrins
TW201113036A (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
JP2022028075A (ja) 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法
US20240368259A1 (en) Antibodies against lefty proteins
JP2025540215A (ja) Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法
TW202602928A (zh) 程序性死亡配體1(pd-l1)嵌合抗原受體及其應用
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK40005045A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
JP2021504492A (ja) 癌治療のための組成物および方法
JP2015199724A (ja) 中和活性を有する抗ｌｒ１１モノクローナル抗体、及びそれを含有してなる医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190711

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200218

R150 Certificate of patent or registration of utility model

Ref document number: 6664219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250